Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021)
Keros Therapeutics' (KROS) quarterly Total Non-Current Liabilities came in at $12.1 million in Q4 2021, up 57.66% YoY from $7.7 million in Q4 2020, and up 5.31% on a QoQ basis from $11.5 million in Q3 2021.
Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021) Analysis & Trends
Keros Therapeutics (KROS) has 3 years of Total Non-Current Liabilities data on file, last reported at $12.1 million in Q4 2021.
- Quarterly Total Non-Current Liabilities rose 57.66% year-over-year to $12.1 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $12.1 million (up 57.66% YoY) and the FY2021 annual result came in at $12.1 million, up 57.66% from the prior year.
- Total Non-Current Liabilities advanced to $12.1 million in Q4 2021, from $11.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $12.1 million in Q4 2021 to a low of $7.4 million in Q3 2020.
- A 3-year average of $9.4 million and a median of $9.3 million in 2021 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Total Non-Current Liabilities declined 25.93% — and 2021, when it surged 57.66%.
- Tracing KROS's Total Non-Current Liabilities over 3 years: stood at $10.3 million in 2019, then declined by 25.93% to $7.7 million in 2020, then surged by 57.66% to $12.1 million in 2021.
- The last three Total Non-Current Liabilities figures came in at $12.1 million (Q4 2021), $11.5 million (Q3 2021), and $7.8 million (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 9.32 Bn |
| 10 | Keros Therapeutics | 216.02 Mn | -41.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 12.08 Mn |
| Sep 30, 2021 | 11.47 Mn |
| Jun 30, 2021 | 7.77 Mn |
| Mar 31, 2021 | 9.31 Mn |
| Dec 31, 2020 | 7.66 Mn |
| Sep 30, 2020 | 7.41 Mn |
| Jun 30, 2020 | 8.99 Mn |
| Mar 31, 2020 | 9.63 Mn |
| Dec 31, 2019 | 10.34 Mn |